blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3043785

EP3043785 - APPLICATION OF R-KETAMINE AND SALT THEREOF AS PHARMACEUTICALS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  01.07.2022
Database last updated on 02.11.2024
FormerThe patent has been granted
Status updated on  23.07.2021
FormerGrant of patent is intended
Status updated on  25.03.2021
FormerExamination is in progress
Status updated on  15.12.2017
Most recent event   Tooltip25.11.2022Change - lapse in a contracting state
State(s) deleted from list of lapses: CY		published on 28.12.2022  [2022/52]
Applicant(s)For all designated states
National University Corporation Chiba University
1-33, Yayoi-cho
Inage-ku
Chiba-shi, Chiba 267-8522 / JP
[2021/34]
Former [2016/29]For all designated states
National University Corporation Chiba University
1-33, Yayoi-cho
Inage-ku
Chiba-shi, Chiba 267-8522 / JP
Inventor(s)01 / HASHIMOTO, Kenji
c/o Center for Forensic Mental Health
Chiba University
1-8-1 Inohana
Chuo-ku
Chiba-shi Chiba 260-8670 / JP
 [2016/29]
Representative(s)Cooley (UK) LLP
22 Bishopsgate
London EC2N 4BQ / GB
[2021/34]
Former [2016/29]Krauss, Jan
Boehmert & Boehmert
Anwaltspartnerschaft mbB
Patentanwälte Rechtsanwälte
Pettenkoferstrasse 20-22
80336 München / DE
Application number, filing date14793319.612.09.2014
[2016/29]
WO2014JP04730
Priority number, dateJP2013019006613.09.2013         Original published format: JP 2013190066
[2016/29]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015037248
Date:19.03.2015
Language:EN
[2015/11]
Type: A1 Application with search report 
No.:EP3043785
Date:20.07.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 19.03.2015 takes the place of the publication of the European patent application.
[2016/29]
Type: B1 Patent specification 
No.:EP3043785
Date:25.08.2021
Language:EN
[2021/34]
Search report(s)International search report - published on:EP19.03.2015
ClassificationIPC:A61K31/135, A61P25/24, A61P25/00, A61P25/18, A61P25/20, A61P25/22, A61P43/00
[2021/13]
CPC:
A61K31/135 (EP,US); A61P25/00 (EP); A61P25/18 (EP);
A61P25/20 (EP); A61P25/22 (EP); A61P25/24 (EP);
A61P43/00 (EP) (-)
Former IPC [2016/29]A61K31/135, A61P25/24
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/29]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:R-KETAMIN UND DESSEN SALZE ALS MEDIKAMENT[2021/13]
English:APPLICATION OF R-KETAMINE AND SALT THEREOF AS PHARMACEUTICALS[2016/29]
French:R-KÉTAMINE ET DE SES SELS COMME MÉDICAMENTS[2021/13]
Former [2016/29]VERWENDUNG VON R-KETAMIN UND SALZ DAVON ALS ARZNEIMITTEL
Former [2016/29]APPLICATION DE R-KÉTAMINE ET SON SEL COMME PRODUITS PHARMACEUTIQUES
Entry into regional phase12.04.2016National basic fee paid 
12.04.2016Designation fee(s) paid 
12.04.2016Examination fee paid 
Examination procedure12.04.2016Examination requested  [2016/29]
28.10.2016Amendment by applicant (claims and/or description)
13.12.2017Despatch of a communication from the examining division (Time limit: M06)
19.06.2018Reply to a communication from the examining division
22.10.2018Despatch of a communication from the examining division (Time limit: M04)
26.02.2019Reply to a communication from the examining division
19.06.2019Despatch of a communication from the examining division (Time limit: M04)
28.10.2019Reply to a communication from the examining division
22.06.2020Despatch of a communication from the examining division (Time limit: M04)
29.10.2020Reply to a communication from the examining division
26.03.2021Communication of intention to grant the patent
15.07.2021Fee for grant paid
15.07.2021Fee for publishing/printing paid
15.07.2021Receipt of the translation of the claim(s)
Divisional application(s)EP21192664.7  / EP3964203
Opposition(s)27.05.2022No opposition filed within time limit [2022/31]
Fees paidRenewal fee
13.09.2016Renewal fee patent year 03
12.09.2017Renewal fee patent year 04
28.09.2018Renewal fee patent year 05
30.09.2019Renewal fee patent year 06
24.09.2020Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  Tooltipdeleted
[2022/52]
Former [2022/47]CY12.09.2021
Cited inInternational search[X]WO2011020061  (PAPALOS DEMITRI [US]) [X] 1-9,11-13,15-17 * the whole document * * claims 1-6,8-17,19-22 * * paragraph [0029] - paragraph [0033] * * paragraph [0032] *;
 [X]US2012225949  (PAPALOS DEMITRI [US]) [X] 1-9,11-13,15-17 * the whole document * * claims 1-6,8-17,19-22 * * paragraph [0028] - paragraph [0032] * * paragraph [0031] *;
 [X]  - A. SCHMIDT ET AL, "Cerebral physiological responses to bolus injection of racemic, S(+)- or R(-)-ketamine in the pig", ACTA ANAESTHESIOLOGICA SCANDINAVICA, (20051013), vol. 49, no. 10, doi:10.1111/j.1399-6576.2005.00838.x, ISSN 0001-5172, pages 1436 - 1442, XP055158242 [X] 1-6 * abstract * * page 1437, column l, line 3, paragraph 4 * * page 1438, column l, line 7 - line 9 *

DOI:   http://dx.doi.org/10.1111/j.1399-6576.2005.00838.x
 [XI]  - SCOTT A. IRWIN ET AL, "Daily Oral Ketamine for the Treatment of Depression and Anxiety in Patients Receiving Hospice Care: A 28-Day Open-Label Proof-of-Concept Trial", JOURNAL OF PALLIATIVE MEDICINE, (20130801), vol. 16, no. 8, doi:10.1089/jpm.2012.0617, ISSN 1096-6218, pages 958 - 965, XP055158543 [X] 7,8,15,16 * the whole document * * abstract * * "Study design"; page 959, column r, paragraph 5 * [I] 1-6,11,12

DOI:   http://dx.doi.org/10.1089/jpm.2012.0617
 [XDI]  - R.PAUL, N.SCHAAFF,F.PADBERG,HANS-JÜRGEN MÖLLER,THOMAS FRODL, "Comparison of racemic ketamine and S-Ketamine in treatment-resistant major depression: Report of two cases", THE WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, U.K., (20090101), vol. 10, no. 3, pages 241 - 244, XP002733798 [XD] 7,8,15,16 * the whole document * * abstract * * "Ketamine administration"; page 242, column r * [I] 1-6,11,12

DOI:   http://dx.doi.org/10.1080/15622970701714370
 [XI]  - Womble, Arthur L., "AANA Journal - April 2013 Volume 81 Number 2 : Effects of Ketamine on Major Depressive Disorder in a Patient With Posttraumatic Stress Disorder", (20130401), URL: http://digitaleditions.sheridan.com/display_article.php?id=1363298, (20141215), XP055158740 [X] 7,10,15-18 * the whole document * * abstract * [I] 11,14
 [XPI]  - JI-CHUN ZHANG ET AL, "R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine", PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, (20140101), vol. 116, doi:10.1016/j.pbb.2013.11.033, ISSN 0091-3057, pages 137 - 141, XP055158236 [XP] 1-6 * the whole document * [I] 7-18

DOI:   http://dx.doi.org/10.1016/j.pbb.2013.11.033
by applicantUS6040479
 WO2007111880
    - DINIZ BD; BUTTERS MA; ALBERT SM; DEW MA; REYNOLDS CF, "Late-life depression and risk of vascular dementia and Alzheimer's disease: systematic review and meta-analysis of community-based cohort studies", B. J. PSYCHIATRY, (2013), vol. 202, pages 329 - 335
    - HASHIMOTO K, "Emerging role of glutamate in the pathophysiology of major depressive disorder", BRAIN RES. REV., (2009), vol. 61, doi:doi:10.1016/j.brainresrev.2009.05.005, pages 105 - 23, XP026669126

DOI:   http://dx.doi.org/10.1016/j.brainresrev.2009.05.005
    - BERMAN RM; CAPPIELLO A; ANAND A; OREN DA; HENINGER GR; CHARNEY DS; KRYSTAL JH, "Antidepressant effects of ketamine in depressed patients", BIOL. PSYCHIATRY, (2000), vol. 47, doi:doi:10.1016/S0006-3223(99)00230-9, pages 351 - 4, XP002565719

DOI:   http://dx.doi.org/10.1016/S0006-3223(99)00230-9
    - ZARATE CA, JR; SINGH JB; CARLSON PJ; BRUTSCHE NE; AMELI R; LUCKENBAUGH BA; CHARNEY DS; MANJI HK, "A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression", ARCH. GEN. PSYCHIATRY, (2006), vol. 63, doi:doi:10.1001/archpsyc.63.8.856, pages 856 - 64, XP002565718

DOI:   http://dx.doi.org/10.1001/archpsyc.63.8.856
    - DIAZGRANADOS N; IBRAHIM L; BRUTSCHE NE; NEWBERG A; KRONSTEIN P; KHALIFE S; KAMMERER WA; QUEZADO Z; LUCKENBAUGH DA; SALVADORE G, "A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression", ARCH. GEN. PSYCHIATRY, (2010), vol. 67, pages 793 - 802
    - BLOCH MH; WASYLINK S; LANDEROS-WEISENBERGER A; PANZA KE; BILLINGSLEA E; LECKMAN JF; KRYSTAL JH; BHAGWAGAR Z; SANACORA G; PITTENGER, "Effects of ketamine in treatment-refractory obsessive-compulsive disorder", BIOL. PSYCHIATRY, (2012), vol. 72, no. 11, doi:doi:10.1016/j.biopsych.2012.05.028, pages 964 - 970, XP055216625

DOI:   http://dx.doi.org/10.1016/j.biopsych.2012.05.028
    - RODRIGUEZ CI; KEGELES LS; LEVINSONA; FENG T; MARCUS SM; VERMES D; FLOOD P; SIMPSON HB, "Randomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept", NEUROPSYCHOPHARMACOLOGY, (2013), vol. 38, pages 2475 - 83
    - FEDER A; PARIDES MK; MURROUGH JW; PEREZ AM; MORGAN JE; SAXENA S; KIRKWOOD K; AAN HET ROT M; LAPIDUS KA; WAN LB, "Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial", JAMA PSYCHIATRY, (2014), vol. 71, pages 681 - 688, XP009186290
    - DIAZGRANADOS N; IBRAHIM LA; BRUTSCHE NE; AMELI R; HENTER ID; LUCKENBAUGH DA; MACHADO-VIEIRA R; ZARATE CA JR, "Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder", J CLIN. PSYCHIATRY, (2010), vol. 71, no. 12, doi:doi:doi:10.4088/JCP.09m05327blu, pages 1605 - 11, XP008161411

DOI:   http://dx.doi.org/
    - WINK LK1; O'MELIA AM; SHAFFER RC; PEDAPATI E; FRIEDMANN K; SCHAEFER T; ERICKSON CA, "Intranasal ketamine treatment in an adult with autism spectrum disorder", J CLIN. PSYCHIATRY, (2014), vol. 75, no. 8, doi:doi:10.4088/JCP.13cr08917, pages 835 - 6, XP009183695

DOI:   http://dx.doi.org/10.4088/JCP.13cr08917
    - KRYSTAL JH; SANACORA G; DUMAN RS, "Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond", BIOL. PSYCHIATRY, (2013), vol. 73, doi:doi:10.1016/j.biopsych.2013.03.026, pages 1133 - 41, XP028557119

DOI:   http://dx.doi.org/10.1016/j.biopsych.2013.03.026
    - DOMINO EF, "Taming the ketamine tiger", ANESTHESIOLOGY, (1965), vol. 113, pages 678 - 86
    - VOLLENWEIDER FX; LEENDERS KL; OEYE I; HELL D; ANGST J, "Differential psychopathology and patterns of cerebral glucose utilization produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET", EUR. NEUROPSYCHOPHARMACOL., (199709), vol. 7, pages 25 - 38
    - PAUL R; SCHAAFF N; PADBERG F; MOELLER HJ; FRODL T, "Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report from two cases", WORLD J. BIOL.PSYCHIATRY, (2009), vol. 10, doi:doi:10.1080/15622970701714370, pages 241 - 244, XP002733798

DOI:   http://dx.doi.org/10.1080/15622970701714370
    - PASLAKIS G; GILLES M; MEYER-LINDENBERG A; DEUSCHLE M, "Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: a case series", PHARMACOPSYCHIATRY, (2010), vol. 43, doi:doi:10.1055/s-0029-1237375, pages 33 - 35, XP008161418

DOI:   http://dx.doi.org/10.1055/s-0029-1237375
    - IRWIN SA; IGLEWICZ A; NELESEN RA; LO JY; CARR CH; ROMERO SD; LLOYD LS, "Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: A 28-day open-label proof-of-concept trial", J. PALLIAT. MED., (2013), vol. 16, doi:doi:10.1089/jpm.2012.0617, pages 958 - 965, XP055158543

DOI:   http://dx.doi.org/10.1089/jpm.2012.0617
    - LI SX; FUJITA Y; ZHANG JC; REN Q; ISHIMA T; WU J; HASHIMOTO K, "Role of the NMDA receptor in cognitive deficits, anxiety and depressive-like behavior in juvenile and adult mice after neonatal dexamethasone exposure", NEUROBIOL. DIS., (2014), vol. 62, doi:doi:10.1016/j.nbd.2013.09.004, pages 124 - 134, XP055432646

DOI:   http://dx.doi.org/10.1016/j.nbd.2013.09.004
    - GOLDEN SA; COVINGTON HE, III; BERTON O; RUSSO SJ, "A standardized protocol for repeated social defeat stress in mice", NAT. PROTOC., (2011), vol. 6, pages 1183 - 1191
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.